je.st
news
Tag: results
DuPont Pioneer Products and Services Yield Impressive Results in 2015
2015-11-17 06:00:00| Corn & Soybean Digest
DES MOINES, Iowa, Nov. 11, 2015 – DuPont Pioneer announced 2015 North American harvest results today – highlighting another year of helping growers reach peak yields and maximize their productivity using Pioneer® brand products and services. read more
Tags: services
results
products
yield
Emisphere Reports Third Quarter 2015 Financial Results
2015-11-16 18:03:29| Biotech - Topix.net
Emisphere Technologies, Inc. today reported financial results for the third quarter ended September 30, 2015, and provided a corporate update. "During the third quarter, we made great strides in commercializing the EligenA technology.
Tags: results
reports
financial
quarter
CPRI Cell Site Architecture, Configuration, and Results
2015-11-16 16:37:23| rfglobalnet Downloads
This video discusses how using Anritsu's MT1000A Network Master field transport tester can rival the BBU while performing quality testing.
Tags: site
results
cell
architecture
Merck Announces Presentation of Results from Two Phase 2 Studies of Investigational Triple-Combination Chronic Hepatitis C Therapy at The Liver Meeting
2015-11-16 14:30:00| Merck.com - Research & Development News
Dateline City: KENILWORTH, N.J. Merck Advances to Part B of C-CREST Phase 2 Clinical Development Program KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of results from the initial phase (Part A) of the companys C-CREST 1 and 2 Phase 2 clinical development program evaluating two investigational all-oral, triple-combination treatment regimens a regimen of grazoprevir1, MK-36822 and elbasvir3; and a regimen of grazoprevir, MK-3682 and MK-84084 in treatment-nave patients with chronic hepatitis C virus (HCV) genotypes (GT) 1, 2 or 3 infection. Language: English Contact: MerckMedia:Doris Li, 908-246-5701Sarra Herzog, 201-669-6570orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: the
results
studies
meeting
Merck Announces Presentation of Phase 3 Results of Investigational Elbasvir/Grazoprevir in People with Chronic Hepatitis C Genotypes 1, 4 or 6 Infection Who Inject Drugs and Are on Opioid Agonist Therapy
2015-11-15 01:00:00| Merck.com - Research & Development News
Dateline City: KENILWORTH, N.J. Results from C-EDGE CO-STAR Presented at The Liver Meeting Show High Sustained Virologic Response After 12 Weeks of Treatment KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of results from the companys Phase 3 C-EDGE CO-STAR clinical trial evaluating the efficacy and safety of the investigational once-daily tablet elbasvir/grazoprevir1 (50mg/100mg) in patients with chronic hepatitis C virus (HCV) genotypes (GT) 1, 4 or 6 infection who inject drugs and are receiving opioid agonist therapy (OAT). Language: English Contact: MerckMedia Contacts:Doris Li, 908-246-5701Sarra Herzog, 201-669-6570orInvestor Contacts:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Sites : [414] [415] [416] [417] [418] [419] [420] [421] [422] [423] [424] [425] [426] [427] [428] [429] [430] [431] [432] [433] next »